Genta-Equine Injection for Horses: Adverse Events

UK Gov

Increase in suspected adverse event reports following use of Genta-Equine 100 mg/ml Solution for Injection for Horses.

We wish to raise awareness of an increase in suspected adverse event reports following use of Genta-Equine 100 mg/ml Solution for Injection for Horses, specifically batches T-001 and V-001.

These reports include:

  • signs of abdominal pain/colic
  • pawing
  • restlessness/agitation
  • groaning
  • shaking/shivering/fasciculation
  • Flehmen response
  • lying down or attempting to lie down
  • staggering
  • increased sweating
  • increased respiratory rate

In all reports received to date, events commenced within minutes of administration and all horses recovered.

Adverse event reports received may include:

  • reports where more than one product was used
  • the product was used off-label

and/or

  • where, on further evaluation, it is considered that there is no causal association between the product and event.

We are working with the companies responsible for the product (Franklin Pharmaceuticals and their distributor Dechra) to investigate these findings and closely monitor reports.

We have also approved a communication from Dechra to veterinary surgeons which provides further information on the events that have been seen, the outcome of the events and investigations that are being carried out.

You will find the Summary of Product Characteristics (SPC) for all veterinary medicinal product authorised for marketing in the UK on our Product Information Database .

No medicine is 100% risk free, the SPC includes information on what adverse events have been known to occur following administration of a particular product, these can be found in section 4.6.

All safety updates to SPCs, including section 4.6, are published on the Veterinary Practice and Supply page under the Medicine Updates section of VMD Connect .

Reporting of adverse events

We strongly encourage anyone who is aware of an adverse event to report directly to the Marketing Authorisation Holder. Please provide all relevant information, including the batch number.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.